Literature DB >> 17846208

Has the degree of contrast enhancement with MR imaging in laryngeal carcinoma added value to anatomic parameters regarding prediction of response to radiation therapy?

R Ljumanovic1, P J W Pouwels, J A Langendijk, D L Knol, P van der Valk, C R Leemans, J A Castelijns.   

Abstract

BACKGROUND AND
PURPOSE: Our aim was to retrospectively investigate the prognostic significance of the degree of contrast enhancement in tumors and its additional value in previously considered MR imaging parameters with regard to local control of laryngeal cancer treated with radiation therapy (RT) alone.
MATERIALS AND METHODS: Pretreatment MR images of 64 consecutive patients (54 men and 10 women, 43-80 years of age) with supraglottic and glottic cancer were retrospectively reviewed on clinical and previously considered MR imaging parameters such as tumor involvement of specific laryngeal anatomic subsites, including laryngeal cartilages, tumor volume, extralaryngeal tumor spread, and, in addition, the degree of contrast enhancement. Clinical and MR imaging parameters were associated with regard to local control at 2 years by using the Cox regression model. "Local control" was defined as absence of primary tumor recurrence.
RESULTS: When using a threshold of the mean average contrast enhancement of 77%, the 2-year local control rate in the groups of patients with a degree of enhancement below and above this threshold was 57% and 70%, respectively (P=.3). Enhancement of tumor tissue in pre-epiglottic space (PES) was low, most probably due to its adipose tissue and poor vascular content, whereas tumor tissue involving paraglottic space (PGS) did enhance. Results of multivariate analysis indicated that the degree of contrast enhancement yielded the prognostic information (P=.07) with 2 independent prognostic factors: primary tumor volume (P=.007) and subglottic extension (P=.002) with regard to local control. Using these previously mentioned 3 MR imaging parameters as potential risk factors, we defined 4 categories, resulting in the following local control rates respectively: 90% for the group without risk factors, 73% for the group with 1, 60% for the group with 2, and finally 0% for the group with 3 risk factors, which was significantly lower than the rates in previous risk groups (P < .001).
CONCLUSION: PES has a lower degree of contrast enhancement than the PGS and may correlate with the worse outcome. Including a low degree of contrast enhancement as a parameter to primary tumor volume and subglottic extension may increase the predictive value of MR imaging for local outcome and may be helpful to identify a subset of patients whose tumors all recurred locally within 2 years after primary RT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846208      PMCID: PMC8134409          DOI: 10.3174/ajnr.A0599

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  24 in total

1.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Authors:  Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

Review 2.  Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging.

Authors:  J Griebel; N A Mayr; A de Vries; M V Knopp; T Gneiting; C Kremser; M Essig; H Hawighorst; P H Lukas; W T Yuh
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

Review 3.  Imaging squamous cell carcinomas of the upper aerodigestive tract: what clinicians need to know.

Authors:  S K Mukherji; H R Pillsbury; M Castillo
Journal:  Radiology       Date:  1997-12       Impact factor: 11.105

4.  Fifteenth Daniel C. Baker, Jr, memorial lecture. What have whole organ sections contributed to the treatment of laryngeal cancer?

Authors:  J A Kirchner
Journal:  Ann Otol Rhinol Laryngol       Date:  1989-09       Impact factor: 1.547

5.  Causes of failure in irradiation of squamous-cell carcinoma of the supraglottic larynx.

Authors:  G H Fletcher; A D Hamberger
Journal:  Radiology       Date:  1974-06       Impact factor: 11.105

6.  Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay.

Authors:  N A Mayr; W T Yuh; V A Magnotta; J C Ehrhardt; J A Wheeler; J I Sorosky; C S Davis; B C Wen; D D Martin; R E Pelsang; R E Buller; L W Oberley; D E Mellenberg; D H Hussey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-10-01       Impact factor: 7.038

7.  Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging.

Authors:  Mark Rijpkema; Johannes H A M Kaanders; Frank B M Joosten; Albert J van der Kogel; Arend Heerschap
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

8.  Intralaryngeal barriers to the spread of cancer.

Authors:  J A Kirchner; D Carter
Journal:  Acta Otolaryngol       Date:  1987 May-Jun       Impact factor: 1.494

9.  MR imaging with Gd-DTPA in lesions of the head and neck.

Authors:  T h Vogl; S Dresel; M Juergens; J Assal; J Lissner
Journal:  J Otolaryngol       Date:  1993-08

10.  Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue.

Authors:  A Becker; G Hänsgen; M Bloching; C Weigel; C Lautenschläger; J Dunst
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-08-01       Impact factor: 7.038

View more
  1 in total

1.  Single-shot turbo spin-echo diffusion-weighted imaging for retinoblastoma: initial experience.

Authors:  P de Graaf; P J W Pouwels; F Rodjan; A C Moll; S M Imhof; D L Knol; E Sanchez; P van der Valk; J A Castelijns
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-27       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.